Safety and effcacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1275-1285

  Meerovitch, Karen ^a   Torkildsen, Gail ^b   Lonsdale, John ^c   Goldfarb, Heidi ^d   Lama, Teresa ^a   Cumberlidge, Garth ^a   Ousler, George W ^e  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b Andover Eye Associates   (United States)

^c Central Maine Eye Care   (United States)

^d SDC Materials   (United States)

^e Ora Inc   (United States)

Author keywords

Controlled adverse environment; Mimetogen; Nerve growth factor

Indexed keywords

AGENTS ACTING ON THE EYE; ARTIFICIAL TEAR; DYE; FLUORESCEIN; KITON GREEN; MIM D 3; PLACEBO; PROTEIN TYROSINE KINASE A; SENSITIVEEYES; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEPHARITIS; CONTROLLED STUDY; CORNEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EVENING DOSAGE; EYE DISCOMFORT; EYE PROTECTION; FEMALE; HUMAN; INSTILLATION SITE IRRITATION; INTRAOCULAR PRESSURE; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT;

EID: 84879483144     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S44688     Document Type: Article

References (32)

1. International Dry Eye Workshop. Research in dry eye: report of the Research Subcommittee of the International Dry Eye Work Shop (2007). Ocul Surf. 2007;5(2):179-193.
2. Rosenthal P, Borsook D. The corneal pain system. Part I: the missing piece of the dry eye puzzle. Ocul Surf. 2012;10(1):2-14.
3. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci. 2003;44(11):4753-4761.
4. McCulley J P, Uchiyama E, Aronowicz JD, Butovich IA. Impact of evaporation on aqueous tear loss. Trans Am Ophthalmol Soc. 2006;104: 121-128.
5. Cadona G, Garcia C, Serés C, Vilesca M, Gispets J. Blink rate, blink amplitude, and tear flm integrity during dynamic visual display terminal tasks. Curr Eye Res. 2011;36(3):190-197.
6. International Dry Eye Workshop. The defnition and classifcation of dry eye disease, report of the Defnition and Classifcation Subcommittee of the International Dry Eye Workshop 2007. Ocul Surf. 2007;5(2): 75-92.
7. Kruse FE, Tseng SC. Growth factors modulate clonal growth and differentiation of cultured rabbit limbal and corneal epithelium. Invest Ophthalmol Vis Sci. 1993;34(6):1963-1976.
8. Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L. Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci. 2000;41(5):1063-1069.
9. Joo MJ, Yuhan KR, Hyon J Y, et al. The effect of nerve growth factor on corneal sensitivity after laser in situ keratomileusis. Arch Ophthalmol. 2004;122(9):1338-1341.
10. Esquenazi S, Bazan HE, Bui V, He J, Kim DB, Bazan NG. Topical combination of NGF and DHA increases rabbit corneal nerve regeneration after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2005;46(9):3121-3127.
11. Coassin M, Lambiase A, Costa N, et al. Effcacy of topical nerve growth factor treatment in dogs affected by dry eye. Graefes Arch Clin Exp Ophthalmol. 2005;243(2):151-155.
12. Patapoutian A, Reichardt L F. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11(3):272-280.
13. de Castro F, Silos-Santiago I, López de Armentia M, Barbacid M, Belmonte C. Corneal innervation and sensitivity to noxious stimuli in trkA knockout mice. Eur J Neurosci. 1998;10(1):146-152.
14. Qi H, Li DQ, Shine HD, et al. Nerve growth factor and its receptor TrkA serve as potential markers for human corneal epithelial progenitor cells. Exp Eye Res. 2008;86(1):34-40.
15. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338(17):1174-1180.
16. Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107(7):1347-1351.
17. Tan MH, Bryars J, Moore J. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration. Cornea. 2006;25(3):352-355.
18. Rios JD, Ghinelli E, Gu J, Hodges RR, Dartt DA. Role of neurotrophins and neurotrophin receptors in rat conjunctival goblet cell secretion and proliferation. Invest Ophthalmol Vis Sci. 2007;48(4):1543-1551.
19. Lambiase A, Micera A, Pellegrini G, et al. In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci. 2009; 50(10):4622-4630.
20. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res. 2004;78(3):379-388.
21. Argüeso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome. Invest Ophthalmol Vis Sci. 2002;43(4):1004-1011.
22. Nakamura Y, Yokoi N, Tokushige H, Kinoshita S. Sialic acid in human tear fuid decreases in dry eye. Jpn J Ophthalmol. 2004;48(6): 519-523.
23. Zhao H, Jumblatt JE, Wood TO, Jumblatt MM. Quantifcation of MUC5AC protein in human tears. Cornea. 2001;20(8):873-877.
24. Li W, Sun X, Wang Z, Li R, Li L. The effect of nerve growth factor on differentiation of corneal limbal epithelial cells to conjunctival goblet cells in vitro. Mol Vis. 2010;16:2739-2744.
25. Maliartchouk S, Feng Y, Ivanisevic L, et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol Pharmacol. 2000;57(2):385-391.
26. Jain P, Li R, Saragovi HU, Cumberlidge G, Meerovitch K. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic effcacy in a rate model in dry eye. Exp Eye Res. 2011;93(4):503-512.
27. Ousler G W, Gomes PJ, Welch D, Abelson MB. Methodologies for the study of ocular surface disease. Ocul Surf. 2005;3(3):143-154.
28. Foulks GN. Challenges and pitfalls in clinical trials of treatments for dry eye. Ocul Surf. 2003;1(1):20-30.
29. Walker PM, Lane KJ, Ousler GW 3rd, Abelson MB. Diurnal variation of visual function and the signs and symptoms of dry eye. Cornea. 2010;29(6):607-612.
30. Liu H, Begley C, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci. 2009;50(8): 3671-3679.
31. Semba C P, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153(6): 1050-1060.
32. Patane MA, Cohen A, From S, Torkildsen G, Welch D, Ousler GW 3rd. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol. 2011;5:633-643.